Thanks for your response. I understand your frustration and I...

Thanks for your response. I understand your frustration and I share it. But I want to be clear. I remain invested because I believe in the drug. I've seen its impact firsthand with my dog Bella, and I genuinely hope it can help the six remaining patients still on NUZ-001 out of the original group of twelve.

That's exactly why it's so important that this program progresses into the Healey ALS Platform trial without further delay. But belief in the science isn't enough. No matter how promising the treatment, it won't succeed without capable leadership managing the regulatory pathway, timelines and investor communication. If there are missteps, they deserve scrutiny - not to undermine the Company, but to protect the future of the drug and the investment behind it. We all want this to succeed.

But blind trust is not the same as good governance - and respectful scrutiny is a part of responsible investment.